Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 14/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299654 | 0.93 | NPC1 (0.40) | NPC1BDKRB1ALDH1A1LMNA | |
| SCHEMBL3441596 | 0.90 | BDKRB1 (0.40) | BDKRB1DRD2DRD3 | |
| SCHEMBL3441594 | 0.90 | BDKRB1 (0.40) | BDKRB1DRD2DRD3 | |
| SCHEMBL4302525 | 0.90 | NPC1 (0.39) | NPC1BDKRB1ALDH1A1LMNA | |
| SCHEMBL702190 | 0.89 | NPC1 (0.37) | NPC1BDKRB1DRD2DRD3ALDH1A1 | |
| SCHEMBL3441720 | 0.85 | BDKRB1 (0.40) | BDKRB1DRD2DRD3ALDH1A1 | |
| SCHEMBL3441702 | 0.85 | BDKRB1 (0.40) | BDKRB1DRD2DRD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3441652 | 0.85 | BDKRB1 (0.40) | BDKRB1DRD2DRD3ALDH1A1 | |
| SCHEMBL3441794 | 0.85 | BDKRB1 (0.40) | BDKRB1DRD2DRD3ALDH1A1 | |
| SCHEMBL3441734 | 0.85 | BDKRB1 (0.40) | BDKRB1DRD2DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | NPC1 2705/4885BDKRB1 1/4885DRD2 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.